Bsure Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 01-07-2024
- Paid Up Capital ₹ 0.10 M
as on 01-07-2024
- Company Age 10 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.50 M
as on 01-07-2024
- Satisfied Charges ₹ 0.20 M
as on 01-07-2024
- Revenue 117.92%
(FY 2023)
- Profit 126.15%
(FY 2023)
- Ebitda 120.99%
(FY 2023)
- Net Worth 126.39%
(FY 2023)
- Total Assets 89.64%
(FY 2023)
About Bsure Pharmaceuticals
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.50 M. The company has closed loans amounting to ₹0.20 M, as per Ministry of Corporate Affairs (MCA) records.
Anshuman Singh and Ankit Singh serve as directors at the Company.
- CIN/LLPIN
U51101BR2014PTC022046
- Company No.
022046
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Feb 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Patna
Industry
Company Details
- Location
Patna, Bihar, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Bsure Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anshuman Singh  | Director | 13-Feb-2014 | Current |
| Ankit Singh | Director | 13-Feb-2014 | Current |
Financial Performance of Bsure Pharmaceuticals.
Bsure Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 117.92% increase. The company also saw a substantial improvement in profitability, with a 126.15% increase in profit. The company's net worth Soared by an impressive increase of 126.39%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bsure Pharmaceuticals?
In 2023, Bsure Pharmaceuticals had a promoter holding of 90.00% and a public holding of 10.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of India Creation Date: 03 Jun 2022 | ₹1.00 M | Open |
Bank Of India Creation Date: 26 Apr 2021 | ₹0.50 M | Open |
Others Creation Date: 27 Feb 2019 | ₹0.20 M | Satisfied |
How Many Employees Work at Bsure Pharmaceuticals?
Unlock and access historical data on people associated with Bsure Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bsure Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bsure Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
